Business
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.\n\n\nManagement will provide an overview of the Company’s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences.\n\n\n\n\nConference:\n\n\n\n\n\n\n\nLD Micro Invitational Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n\nLuxe Hotel, Los Angeles\n\n\n\n\n\n\n\n\nDate:\n\n\n\n\n\n\n\nWednesday, June 7\n\n\n\n\n\n\n\n\nTime:\n\n\n\n\n\n\n\n11:30 am Pacific Time | 2:30 pm Eastern Time\n\n\n\n\n\n\n\nThe presentation at the LD Micro conference will be live-streamed on the event website at https://ldinv13.sequireevents.com/.\n\n\n\n\n \n\n\n\nConference:\n\n\n\n\n\n\n\nJefferies Global Healthcare Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\n\nMarriott Marquis, New York City\n\n\n\n\n\n\n\n\nDate:\n\n\n\n\n\n\n\nFriday, June 9\n\n\n\n\n\n\n\n\nTime:\n\n\n\n\n\n\n\n7:30 am Pacific Time | 10:30 am Eastern Time\n\n\n\n\n\n\n\nWebcast access for the Jefferies conference will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of the Jefferies conference will be available for 90 days.\n\n\nAbout Equillium\n\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under ev...